PMDA exchanges opinions with external experts on issues to be considered in scientific matters.
Completed
(note) Includes consideration by the Science Board Subcommittees (2012 to 2024)Drugs
- Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes (August 4, 2021 to September 22, 2022)
- Subcommittee on Microbiome (August 5, 2020 to September 17, 2021)
- Subcommittee on AMR (August 10, 2018 to July 9, 2019)
- Subcommittee on Rare Cancers (October 19, 2016 to October 16, 2017)
- Subcommittee on Pharmaceuticals Development (December 19, 2016 to December 27, 2017)
- Subcommittee on Placebo-controlled Studies (October 3, 2014 to January 14, 2016)
- Subcommittee on Non-clinical Studies (August 4, 2014 to May 13, 2015)
- Pharmaceuticals Subcommittee (September 24, 2012 to February 21, 2014)
- Bio-products Subcommittee (September 24, 2012 to February 21, 2014)
Medical Devices
- Subcommittee on Software as a Medical Device Utilizing AI and Machine Learning (July 26, 2022 to June 19, 2023)
- Subcommittee on Computer Simulation (December 16, 2019 to January 21, 2021)
- Subcommittee on AI (Artificial Intelligence) (January 13, 2017 to October 6, 2017)
- Subcommittee on Application of Numerical Analysis to Non-clinical Evaluation (August 4, 2014 to March 1, 2016)
- Subcommittee on Evaluation of Medical Devices in Pediatric Use (October 17, 2014 to October 19, 2015)
- Medical Devices Subcommittee (September 24, 2012 to February 17, 2014)
Regenerative Medical Products
- Subcommittee on Cell and Gene Therapy Products Produced in vivo (June 1, 2023 to May 23, 2024)
- Subcommittee on Genome Editing (November 8, 2018 to October 29, 2019)
- CPC (Cell Processing Center) Subcommittee (June 12, 2014 to May 14, 2015)
- Cellular and Tissue-based Products Subcommittee (September 24, 2012 to February 3, 2014)